Cite
HARVARD Citation
Chen, X. et al. (n.d.). 804 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy. Journal for immunotherapy of cancer. p. A481. [Online].